CY CLOSPORIN E is an e ffe ctive drug in acute ex acerbation s of co rtico s te ro id r es is tant ulcer ative colitis , but its e fficacy to m ain tain dis eas e re m is s ion is n ot clear. Cyclos po rin e m ay no t be as effectiv e in Cro h n 's dis e as e . How eve r, bein g a rap idly acting im m un os upp r es s ant, cyclos p o rin e m ay be a v aluable th erap eutic op tion in th e s h ort-ter m to tr e at cortico s te r oid re s is tan t Cro h n 's dis eas e and ulce rative co litis .
Introduction
The efficacy of immunosuppressive drugs like azathioprine and 6-mercaptopurine to treat the chronic inflammatory bowel diseases (IBD) ulcerative colitis (UC) and Crohn's disease (CD) is now generally accepted. However, a major draw back to the use of these immunosuppressants is the 2-3 month delay in onset of their clinical action, thereby limiting their role in severe acutely active disease.
The success of the rapidly acting immunosuppressive drug cyclosporine in solid organ transplantation and chronic inflammatory diseases such as psoriasis and rheumatoid arthritis paved the way to determine the efficacy of cyclosporine in IBD.
The following review will focus on clinical response in controlled trials, pharmacology, side effects and toxicity of cyclosporine treatment in CD and UC.
Cyclosporine in Crohn's Disease
Numerous open studies have suggested that cyclosporine may be effective in active CD w hich has not responded to conventional treatment including corticosteroids, aminosalicylates and antibiotics. 1 However, only four controlled trials of cyclosporine for the treatment of CD have been published. 2 -6 In three of these studies a total number of 633 patients was treated with low-dose oral cyclosporine (5 mg/ kg/day and w hole blood concentrations ranging from 100-250 ng/ml) or placebo. [4] [5] [6] These studies failed to demonstrate any significant beneficial effect of chronic low-dose oral cyclosporine for chronically active CD or for remission maintenance. Given alone as initial treatment, cyclosporine was less effective than conventional treatment. 7 Only one controlled study using high-dose oral cyclosporine (5-7.5 mg/kg/day) for CD has been published. 2, 3 At 3 months 59% of the patients treated with cyclosporine had improved compared with 32% in the placebo group. 2 The whole blood concentrations were higher in the responders (471 ng/ml) than in the nonresponders (309 ng/ml). However, the beneficial effect did not persist after cyclosporine was stopped. 3 Two studies have suggested efficacy of cyclosporine for fistulizing CD. 8, 9 At present, it seems reasonable to limit the use of cyclosporine to patients with severely active CD who failed to respond to corticosteroids and aminosalicylates, and preferably in a clinical research setting.
Cyclosporine in Ulcerative Colitis
Several open studies have reported a beneficial effect of cyclosporine in the treatment of UC. 10, 11 Only one small controlled trial showed that cyclosporine, given in an intravenous dosage of 4 mg/kg/day comparable with an oral dosage of 12-16 mg/kg/day, w ill induce a remission in 83% of patients w ith severe ulcerative colitis compared w ith 0% of the placebo-treated patients. 12 It is important to realize that only 45% of these patients avoided colectomy during 6 months of follow -up. 13 One controlled trial of low-dose cyclosporine enemas for left-sided UC had negative results.
The general experience of these studies in UC is that 50-70% of the patients will require surgery during the following 12 months after starting cyclosporine therapy. However, using cyclosporine treatment some patients, especially those with a first attack, w ill not lose their colon. In others, colectomy can be performed when the patient is in a better physical condition and the ileo-anal pouch anastomosis done as a one-stage procedure w ithout the need of a stoma. Recently, an excellent paper has been published describing in detail guidelines how to use and monitor cyclosporine treatment in UC patients. 15 
Pharmacology
Cyclosporine is a lipophilic peptide which inhibits T-helper cell interleukin-2 (IL-2) mRNA transcription and production, and also the release of other lymphokines such as interferon-gamma, IL-3, IL-4, IL-5, and tumour necrosis factor-alpha, resulting in altered T cell and B cell function. 16, 17 At present, it is not known w hether these effects on cellular and humoral immunity account for any therapeutic effect in IBD. Alternatively, neutralization of the neutrophil chemotactic properties of extracellular cyclophillin by cyclosporine has been proposed as the primary mode of action in IBD. 18 This hypothesis could explain the better responsiveness to cyclosporine in UC compared w ith CD, because in UC neutrophil influx may play a bigger role than in CD. Although the effectiveness of cyclosporine in treating IBD could be dose related, there is also evidence that low -dose cyclosporine may even worsen tissue inflammation and injury by changing specific lymphocyte subpopulations. 18 In mice, it has been shown that low-dose cyclosporine causes a switch from a T-helper 1 to a T-helper 2 response thereby augmenting the inflammatory response. 19 The distribution and elimination kinetics of cyclosporine in patients with CD do not differ from those in other patient groups or controls, whereas the extent and rate of oral bioavailability may be decreased. 20, 21 The absorption of cyclosporine can be described by zero-order kinetics in patients with CD, implying that the gut transit time is important for the amount of cyclosporine absorbed. 20 In one study, 10% of patients w ith CD showed cyclosporine malabsorption based on blood levels. 4 In addition, absorption of cyclosporine is significantly affected by bile salts. Recently, a new formulation of cyclosporine -Neoralhas been developed, w hich consists of a microemulsion of cyclosporine employing a surfactant, a lipophilic solvent, a hydrophilic solvent, and a cosolvent. 22 This new formulation ensures rapid release of cyclosporine w ithin the gastrointestinal tract and a more uniform presentation to the absorptive surface of the upper small bowel. This results in consistent dispersion of the drug in the gastrointestinal tract without the need for additional emulsifiers like bile salts. Studies have demonstrated that in patients w ith CD who have problems absorbing cyclosporine, conversion to Neoral results in correction of cyclosporine malabsorption. 22 At present, however, it remains unclear whether initial therapy with intravenous cyclosporine is superior to oral administration.
Side Effects and Toxicity
Being a powerful immunosuppressant, cyclosporine also has potential side effects including: renal insufficiency (6%), hypertension (11%), infectious complications (3%), severe neurological disorders including epilepsy (1%), paresthesias (26-70%), tremor (7%), headache (5%), hypertrichosis (13%), gingival hyperplasia (2%), and anaphylaxis (0.3%) 23 -26 (Table 1) . Cyclosporine is metabolized in the liver and both cyclosporine and its metabolites are excreted in bile and little cyclosporine appears in the urine. Renal impairment does not alter the elimination of cyclosporine. Any drug that inhibits the cytochrome P-450 system will increase cyclosporine levels (ketoconazole, fluconazole, cimetidine, erythromycin, diltiazem, verapamil), whereas drugs that induce the P-450 system will decrease cyclosporine levels (rifampicin, phenobarbital, phenytoin, carbamazepine).
Nephropathy due to long-term cyclosporine treatment is an important issue. The direct effect of cyclosporine is a vasoconstriction of preglomerular arterioles with a secondary decrease in glomerular filtration rate and an increased proximal tubular fractional reabsorption rate. This may result in increased tubular transit time and tubular atrophy and
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Mediators of Inflammation · Vol 7 · 1998 Table 1 . Side effects of cyclosporine Side effects which tend to occur during chronic administration interstitial fibrosis. 20 It has been suggested that onefifth of patients w ith autoimmune diseases treated with cyclosporine have histological evidence of nephropathy. 27 A few case reports dealing w ith severe and sometimes fatal opportunistic infections have been reported. 23 -26 Importantly, these infections occurred during high-dose cyclosporine treatment in combination with corticosteroids.
Conclusions
Cyclosporine is an effective therapeutic option in acute exacerbations of UC not responding to corticosteroids. When given orally, its long-term efficacy is questionable. Low-dose oral cyclosporine is not effective in either quiescent or active CD. Cyclosporine can be used as rescue therapy to 'buy time': most patients w ho benefit on the short-term from cyclosporine, w ill require further treatment for their IBD in the form of follow-up surgery or other remission maintaining drugs like azathioprine or 6-mercaptopurine. The introduction of a new formulation of cyclosporine has improved the absorption kinetics of the drug and the consistency of plasma levels after oral dosage. Cyclosporine side effects, especially nephrotoxicity, are common necessitating adequate monitoring.
